Obinutuzumab in Chinese Real-world Patients With iNHL

NCT05968001 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Lymphomas Non-Hodgkin's B-Cell

Interventions

DRUG: Obinutuzumab

Sponsor

Affiliated Hospital of Nantong University